Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Bladder Cancer
Clinical trial register · United States · industry-sponsored

Bladder Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9147 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Oct 2026, 03:16 UTC
9147
Studies in scope
industry-sponsored, all four open statuses
4965
Recruiting now
open to new participants
2197
Lead sponsors
across recruiting studies
Top states
California 18 Florida 12 New York 10 Georgia 10 Illinois 9
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Bladder Cancer trials in the USA

28 of 9147 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Early Phase 1
40
Massachusetts, Michigan, New York
2026-09-01
Recruiting
SystImmune Inc.
Phase 3
520
Georgia
2026-09
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Novartis Pharmaceuticals
Phase 1
156
Nebraska
2026-06-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Georgia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-04-23
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Michigan, New Jersey
2026-03-25
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
Merck Sharp & Dohme LLC
Phase 1/2
45
California, New Jersey, South Carolina, Texas
2025-12-09
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Recruiting
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Active, closed
Pangea Laboratory LLC
Observational
80
Minnesota
2025-06-03
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
California, Florida, Illinois, Iowa, New York, North Carolina, Ohio, Pennsylvania
2024-03-28
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Active, closed
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
Arcus Biosciences, Inc.
Phase 1
40
Arizona, Florida, Illinois, Michigan, Minnesota, New Jersey, Ohio, Texas
2023-10-13
Recruiting
Early is Good Inc.
Observational
500
Arkansas, Indiana, Missouri
2023-07-26
Active, closed
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
NCT05520099Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
Elephas
Observational
416
Arkansas, California, Florida, Kentucky, Maryland, New Jersey, New York, North Carolina
2023-06-26
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2023-03-23
Active, closed
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
NCT05696444Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
Medtronic - MITG
Not applicable
144
California, Illinois, New York, North Carolina, Ohio, Washington
2022-12-14
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
Adela, Inc
Observational
7,000
California, Florida, Georgia, Indiana, Kentucky, Minnesota, Ohio, Oregon
2022-05-03
Active, closed
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
240
Arizona, California, Kansas, Maryland, Missouri, New Jersey, New York, Tennessee
2022-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Arizona, California, Colorado, Florida, Indiana, Iowa, Kentucky, New York
2021-04-21
Active, closed
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
Tempus AI
Observational
1,000
Texas
2020-10-19
Active, closed
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
ImmunityBio, Inc.
Phase 2/3
190
Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois
2017-06-02
Recruiting
Photocure
Observational
4,400
Alabama, Arizona, California, District of Columbia, Georgia, Illinois, Indiana, Kansas
2014-04
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/bladder-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,147 studies in total at the last sync on 21 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Bladder Cancer.

How many Bladder Cancer trials are recruiting in the US?

14 of the 28 studies on this page are recruiting new participants as of the 21 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bladder Cancer), 28 studies
PhaseStudiesRecruitingShare
Observational9632.1%
Phase 37225%
Phase 14314.3%
Phase 1/23210.7%
Phase 2/3217.1%
Early Phase 1103.6%
Not applicable103.6%
Phase 2103.6%

Most active sponsors

Lead sponsors with the most studies (Bladder Cancer)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC53
Elephas21
Photocure22
UroGen Pharma Ltd.20
Adela, Inc11
Arcus Biosciences, Inc.10
AstraZeneca11
CG Oncology, Inc.10
Daiichi Sankyo11
Early is Good Inc.11

Top states

Top states (Bladder Cancer), by number of studies with a site there
StateStudies
California18
Florida12
Georgia10
New York10
Illinois9
Arizona8
New Jersey7
Arkansas6
Colorado6
Indiana6
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.